Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ÅF - one of Sweden's most popular employers

ÅF is proud to be one of Sweden's most popular employers among young professionals, and also industry best.Universum Global publishes its annual ranking of the most attractive employers in Sweden among young professionals. Karriärbarometern is a comprehensive survey of career, work life and future. More than 19,000 professional graduates have participated in the survey and voted for Sweden's most attractive employer.  This year’s result shows that ÅF is ranked as industry best, and also takes the fourth place in the two categories M.Sc. Engineers and B.Sc. Engineers, when Sweden's young

The ISR Immunolide Platform Expanded into Hepatitis B

Screenings of the substances from ISR’s Immunolide platform have identified a new pharmaceutical lead candidate, ISR051, which has immune stimulating effects, apparently advantageous in the treatment of hepatitis B. ISR now plans to expand its research and development portfolio to encompass, apart from HIV, tuberculosis and cancer, also hepatitis B.The hepatitis B virus (HBV) is one of the world’s most ubiquitous diseases, where WHO estimates over two billion people have or have had the disease and 240 million are chronic bearers. Nearly 700,000 people die in this disease every year, and 25%

The preclinical development program of SI-053 is complete

The results of the two remaining preclinical studies are now available. The toxicological studies on SI053 and its formulation showed expected results. The study on the excipient was a long-term studyto confirm the safety of the hydrogel in the brain. Neither neurological side effects nor any effects onblood cells were noted. There were no serious adverse events in the GLP-toxicity study of SI-053. The effects noted were dueto the active pharmaceutical ingredient temozolomide, such as an effect on blood cells which wasexpected. Thus, the overall results of the GLP-tox study

Highlight Games enters into a strategic distribution agreement for the US market

The gaming specialist Highlight Games, a Cherry AB (publ) – STO: CHER-B.ST subsidiary, has entered into a strategic distribution agreement with Reno based iGaming firm Spin Games LLC (“Spin”) to distribute Highlight Games’ exclusive virtual sports content in regulated iGaming, sports betting and lottery markets in the United States of America.Under the arrangement Spin will integrate Highlight Games’ virtual sports content, that uses historic footage of sportings events, on to its remote game server (“The ROC”) and distribute such content in the US markets. In addition, Highlight Games will

Scandinavian ChemoTech receives a new order from Gold Lite in Myanmar

Scandinavian ChemoTech AB has today received an additional order of EUR 5,000 from Gold Lite in Myanmar.Gold Lite in Singapore, a sister company to ABEX in Malaysia, is responsible for all the operations in Myanmar. The delivery and launch of IQwave™ and D-EECT in Myanmar is scheduled to take place at the end of the current year. This order is a supplementary order for the previous one, which was acknowledged by the end of September, says Mohan Frick, CEO at ChemoTech. For more information, please contact: Mohan Frick, CEO +46 (0)10-218 93 00 info@chemotech.se This

Invitation to Capital Markets Day on November 21

Vitrolife AB (publ) hereby invites analysts, investors, shareholders and journalists to a Capital Markets Day on November 21.We will talk about Vitrolife’s business, which assists in making many people’s desire to have children a reality. We will give an update on the market trends and the strategy together with an update on the operative and financial development. Furthermore, we will present the new partnership with Illumina on preimplantation genetic testing. There will be an opportunity to visit one of our production facilities between approx. 15:30-16:30. The presentations will be held

Skanska to rehabilitate the Manhattan Bridge for the New York City Department of Transportation, USA, for USD 76 M, about SEK 675 M

Skanska has signed a contract with the New York City Department of Transportation (NYCDOT) to rehabilitate the iconic Manhattan Bridge. The contract is worth USD 76 M, about SEK 675 M, which will be included in the US order bookings for the third quarter of 2018.The bridge, which was originally built in 1909, is the most heavily traveled of the East River bridges, and accommodates more than 85,000 vehicles, 4,000 bicyclists, and 340,000 transit riders on an average weekday. As part of this contract, Skanska is performing significant structural and component rehabilitation on various aspects

NeuroVive reports first NeuroSTAT clinical efficacy signal in TBI

Lund, Sweden, 4 October 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company’s investigational compound NeuroSTAT. The results provide an early signal of efficacy derived from time-based changes in biomarker levels that correlate with NeuroSTAT drug administration.Patient samples from the previously completed CHIC study have been analyzed in a research collaboration with Kevin K.W. Wang, Ph.D., at

Climeon increases capacity with new test site in Kista

Climeon increases the capacity with a new test center for development and testing of heat power modules in Kista. The new facility increases Climeon's total delivery capacity.The new testing facility is located in connection to the company's new office in Kista, with the possibility of more customer demonstrations, faster development verification, extended test time and a unified organization. - We are building the business to become a globally leading product company within energy technology, says CEO Thomas Öström. Therefore, it is strategic for us to gather the organization in one

Dairy deliveries to shops powered by waste – Valio’s first biogas-fueled delivery vehicle taken into use

The Finnish dairy manufacturer Valio’s first biogas-fueled delivery vehicle was taken into service in the Helsinki Metropolitan Area in September. Valio also takes part in biogas production by supplying waste generated in food production to Gasum’s biogas plants.For many years, Valio has been testing a variety of vehicles using environmentally friendly fuels. The biogas pilot started this autumn was inspired by Valio’s circular economy thinking where the aim is to recover the waste generated in dairy production. In addition to taking part in biogas production, Valio is also introducing a

Åsa Mindus Söderlund appointed new CEO of Försäkringsaktiebolaget Avanza Pension

Åsa Mindus Söderlund, currently CEO of Avanza Fonder AB, has been appointed the new CEO of Försäkringsaktiebolaget Avanza Pension. Åsa will take over the position before the end of the year, and recruitment of a new CEO for the fund management company will begin immediately.In early September it was announced that the current CEO of the pension company, Annika Saramies, had decided to leave Avanza after 11 years. Åsa Mindus Söderlund, who took over as CEO of Avanza Fonder AB in August 2017, has been named the new CEO of Försäkringsaktiebolaget Avanza Pension. Åsa will take up her new post

The Canadian Intellectual Property Office intends to grant Idogen’s patent application for tolerogenic cell therapy

Idogen AB (”Idogen”) today announces that the Canadian Intellectual Property Office (”CIPO”) has issued a “Notice of Allowance”, which means that it intends to grant Idogen’s patent application. During 2017, the company was granted patents for its tolerogenic cell therapy in the USA, Europe and Japan complementing an already granted patent in Europe for another aspect of the technology. The Canadian patent will provide Idogen’s tolerogenic cell therapy with broad protection in a key market and significantly strengthens the company’s patent portfolio.The Canadian Intellectual Property Office

Veidekke ASA: Sold 196 residential units at a value of NOK 900 million

Veidekke sold 196 residential units in the third quarter of 2018. Overall, Veidekke’s sales of residential units amounted to NOK 900 billion in the third quarter of 2018. The number of own-account residential units under construction is 2,809.Overall activities are on level with the second quarter of 2018 and the third quarter one year ago. The number of units under construction has declined from the second quarter of 2017, and is currently at 2,809 units, compared with 3,366 a year ago. Veidekke’s share in the quarter is 2,260 units. The sales ratio for units under construction is 80%.

Bonava to take part in Expo Real Trade Fair in Munich

On 8-10 October, Bonava will take part in the annual Expo Real International Trade Fair for Property and Investment in Munich, Germany. The goal is to meet with investors to brand Bonava as the leading housing developer.Expo Real is a meeting place for Europe’s foremost players in the industry. Investors, residential developers, politicians and other industry stakeholders will meet for two days to discuss construction, housing and properties. Bonava’s stand at the trade fair will serve as a meeting place for discussions on residential construction and development as well as a platform

Presentation of Sandvik´s report of the third quarter 2018

Sandvik will publish its third quarter results on Tuesday, 23 October 2018 at approximately 12.00 CEST. A combined webcast and conference call for investors, analysts and financial media will be held at 13.30 CEST. The report will be presented in a webcast and conference call by Björn Rosengren, President and CEO as well as by Tomas Eliasson, CFO. The presentation will be broadcasted live on our website home.sandvik Dial-in details for the conference call: SE: + 46 (0) 8 566 426 92 UK: +44 (0) 203 008 98 08 US: +1 855 831 59 44 From about 12.30 CEST presentation

Lantmännen’s result in line with the previous year – future effects of the summer’s drought difficult to fully predict

Lantmännen’s result for the first eight months of 2018, after net financial items and adjusted for items affecting comparability, amounts to 1 058 MSEK – compared to last year’s result of 1 112 MSEK.”Lantmännen as a whole continues to develop well, although the second four-month period has obviously been dominated by the dry and warm summer, which has had a major impact both on our own operations and on our owners’ farms. Comprehensive measures have been taken to handle the extreme weather; for example, Lantmännen has introduced an action package for our members, to mitigate the effects of

Read original

Magnus and Thistle Options exercised

EnQuest PLC, 4 October 2018 Magnus and Thistle Options exercised EnQuest PLC ('EnQuest'), an independent oil and gas production and development company listed on the London and Stockholm stock exchanges (ENQ.L and ENQ.ST), is pleased to announce that following Shareholder approval at the Company's General Meeting on 1 October 2018, it has exercised its options with BP relating to the Magnus field and associated infrastructure and the Thistle and Deveron fields. The Magnus acquisition, which is targeted for completion by year-end 2018, subject to requisite regulatory and third party

Bactiguard partners with Mediplast in Scandinavia

Bactiguard partners with Mediplast, a medical device company and healthcare supplier in the Nordic region, for sales and distribution in Sweden, Norway and Denmark. By using the Mediplast sales force, the Swedish healthcare providers can be covered more efficiently. At the same time, the collaboration provides a platform for launching the BIP portfolio in Norway and Denmark, markets where Bactiguard is not present today.“In the past couple of years, we have successfully established agreements with the largest Swedish county councils, and currently cover 70% of the Swedish population. This

IRRAS Provides Update on the Recertification Process of the CE Mark for the IRRAflow® Catheter

- Due to large backlog of applications, the Notified Body, LNE/G-MED, now expects completion of the process around year’s endStockholm, Sweden, October 4, 2018 – IRRAS AB (Nasdaq First North Premier: IRRAS) announced today that it has received further information from its Notified Body, LNE/G-MED, regarding the CE Mark of the IRRAflow catheter. The Notified Body completed its initial review of the IRRAS recertification application and has provided a list of questions and requests for some clarifications. These requests by LNE/G-MED should all be addressable in existing IRRAS documentation,

AcadeMedia increases the number of children and students with 4.8 percent organically and 15.7 percent in total

The number of children and students in AcadeMedia’s three school segments increased with 15.7 percent for the first quarter of 2018/19 compared with the corresponding period last year. This means that the average number of children and students attending our preschools and schools was 78 770 (68 098) during the quarter. The figures are preliminary. AcadeMedia has made several acquisitions during the last year. Vindora with 36 upper secondary schools was acquired in November last year and KTS in Germany was acquired during the spring term of 2018. These strategic acquisitions in

SRV to implement extension of SOK logistics centre in Sipoo

SRV GROUP PLC                     INVESTOR NEWS                          4 OCTOBER 2018, AT 09.00 SRV to implement extension of SOK logistics centre in Sipoo SOK has selected SRV as the main contractor in an extension project for Finland’s largest daily consumer goods logistics centre. Construction work on the extension of the property, located in Sipoo’s Bastukärr business park, will be launched immediately and the project will be completed in June 2020. SRV will implement the project as a project management contract. The final contract price is not disclosed. The volume of

Swedrive invests for the future

Swedrive has recently opened a new 2700 square meter production hall in Lagan, 100 km south of Jönköping. With the expansion they now have a total of over 6000 square meters. Several new machines have also been acquired and since 2016 Swedrive have made investments in total of 54 MSEK. The expansion and machine investments are the first steps in their commitment to strengthening the position as one of Northern Europe's leading manufacturers of electromechanical solutions. Swedrive will also modernize their assembly lines and build a major development and testing centre as well as a brand-

Redeye: Westpay - Delays, but the potential remains the same

Just like we expected we saw a small sales drop during Q2’18. Announcements regarding larger orders have been scarce the last months; a major product revamps that Westpay has been working on is the likely explanation for the hesitant customer behavior. We have adjusted our projections downwards which also leads to a lower Base-case. However, our Valuation range remains almost intact as we believe the long-term potential has not been altered despite the delays and quarterly fluctuations. Read more and download the latest research update: http://bit.ly/2yg8f2i Start following companies

A challenging quarter for the MQ Group

Sales during the fourth quarter did not develop in line with expectations. The unusually hot summer had an adverse impact on sales, leading to more items being sold at sale prices and a delayed start to the autumn season. The whole year has been a challenge in terms of decreased customer traffic and sales, primarily in the MQ chain, leading to lower profitability for the Group. The Joy chain continues to see increased footfall, and sales are on a par with last year. The Group’s new CEO Ingvar Larsson started on 20 August. We now put a weak quarter behind us and turn our sights to the future.

There are no items matching the current filter
There are no more items matching the current filter
Back to top